| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 66 | 2022 | 608 | 5.550 |
Why?
|
| Genetic Predisposition to Disease | 34 | 2021 | 529 | 3.790 |
Why?
|
| Humans | 142 | 2022 | 4119 | 3.140 |
Why?
|
| Female | 103 | 2021 | 2147 | 2.880 |
Why?
|
| Pedigree | 70 | 2021 | 304 | 2.860 |
Why?
|
| Male | 98 | 2021 | 1811 | 2.860 |
Why?
|
| Mutation, Missense | 24 | 2021 | 124 | 2.410 |
Why?
|
| Microcephaly | 18 | 2022 | 65 | 2.400 |
Why?
|
| Intellectual Disability | 16 | 2021 | 122 | 1.980 |
Why?
|
| Exome | 31 | 2021 | 124 | 1.970 |
Why?
|
| Child | 52 | 2022 | 557 | 1.900 |
Why?
|
| Homozygote | 30 | 2021 | 117 | 1.820 |
Why?
|
| Phenotype | 31 | 2022 | 479 | 1.770 |
Why?
|
| Ovarian Neoplasms | 7 | 2020 | 52 | 1.460 |
Why?
|
| Adult | 38 | 2021 | 944 | 1.430 |
Why?
|
| Adolescent | 37 | 2021 | 493 | 1.320 |
Why?
|
| Genetic Association Studies | 15 | 2021 | 122 | 1.250 |
Why?
|
| Germ-Line Mutation | 11 | 2020 | 54 | 1.250 |
Why?
|
| Child, Preschool | 37 | 2021 | 378 | 1.240 |
Why?
|
| Epilepsy | 8 | 2021 | 53 | 1.190 |
Why?
|
| Breast Neoplasms | 6 | 2020 | 312 | 1.190 |
Why?
|
| Young Adult | 25 | 2021 | 345 | 1.020 |
Why?
|
| Nerve Tissue Proteins | 7 | 2021 | 74 | 0.920 |
Why?
|
| Developmental Disabilities | 6 | 2021 | 29 | 0.900 |
Why?
|
| DNA-Binding Proteins | 9 | 2021 | 139 | 0.860 |
Why?
|
| Infant | 24 | 2021 | 267 | 0.860 |
Why?
|
| Middle Aged | 22 | 2021 | 843 | 0.830 |
Why?
|
| Animals | 32 | 2021 | 1545 | 0.830 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2020 | 552 | 0.820 |
Why?
|
| Abnormalities, Multiple | 10 | 2020 | 86 | 0.820 |
Why?
|
| Codon, Nonsense | 9 | 2021 | 54 | 0.810 |
Why?
|
| Cell Cycle Proteins | 7 | 2021 | 33 | 0.810 |
Why?
|
| High-Throughput Nucleotide Sequencing | 15 | 2021 | 173 | 0.810 |
Why?
|
| Sequence Analysis, DNA | 18 | 2021 | 249 | 0.800 |
Why?
|
| DNA Mutational Analysis | 13 | 2018 | 122 | 0.770 |
Why?
|
| Hearing Loss, Sensorineural | 4 | 2020 | 10 | 0.760 |
Why?
|
| Epilepsy, Rolandic | 6 | 2018 | 11 | 0.730 |
Why?
|
| Loss of Function Mutation | 4 | 2020 | 29 | 0.670 |
Why?
|
| Epilepsy, Generalized | 5 | 2018 | 21 | 0.640 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2018 | 4 | 0.640 |
Why?
|
| RNA Helicases | 1 | 2018 | 13 | 0.640 |
Why?
|
| Genetic Variation | 9 | 2019 | 189 | 0.630 |
Why?
|
| Molecular Sequence Data | 20 | 2015 | 301 | 0.630 |
Why?
|
| Haplotypes | 10 | 2022 | 122 | 0.630 |
Why?
|
| Cullin Proteins | 1 | 2017 | 4 | 0.620 |
Why?
|
| Leukoencephalopathies | 1 | 2017 | 4 | 0.620 |
Why?
|
| Chromosome Mapping | 9 | 2020 | 146 | 0.610 |
Why?
|
| Sequence Deletion | 5 | 2019 | 51 | 0.610 |
Why?
|
| Heterozygote | 11 | 2021 | 94 | 0.590 |
Why?
|
| Amino Acid Sequence | 18 | 2016 | 186 | 0.570 |
Why?
|
| Zebrafish | 13 | 2020 | 57 | 0.560 |
Why?
|
| RNA Splicing | 4 | 2021 | 55 | 0.550 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2018 | 22 | 0.550 |
Why?
|
| Genes, Recessive | 8 | 2018 | 44 | 0.550 |
Why?
|
| Alleles | 10 | 2021 | 221 | 0.540 |
Why?
|
| Progeria | 4 | 2021 | 11 | 0.540 |
Why?
|
| Receptors, GABA-A | 4 | 2018 | 8 | 0.540 |
Why?
|
| Genetic Linkage | 10 | 2021 | 46 | 0.530 |
Why?
|
| Aged | 12 | 2020 | 580 | 0.530 |
Why?
|
| Base Sequence | 15 | 2016 | 275 | 0.530 |
Why?
|
| Models, Molecular | 13 | 2020 | 50 | 0.530 |
Why?
|
| Consanguinity | 12 | 2021 | 56 | 0.510 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2020 | 13 | 0.510 |
Why?
|
| Retinal Degeneration | 4 | 2020 | 9 | 0.500 |
Why?
|
| Spastic Paraplegia, Hereditary | 4 | 2017 | 13 | 0.500 |
Why?
|
| Eye Abnormalities | 5 | 2018 | 15 | 0.490 |
Why?
|
| Muscular Diseases | 4 | 2021 | 17 | 0.490 |
Why?
|
| Transcription Factors | 8 | 2021 | 256 | 0.480 |
Why?
|
| RNA-Binding Proteins | 3 | 2021 | 73 | 0.480 |
Why?
|
| Mitochondrial Proteins | 3 | 2019 | 35 | 0.470 |
Why?
|
| Cleft Palate | 3 | 2021 | 103 | 0.460 |
Why?
|
| RNA Polymerase III | 3 | 2018 | 5 | 0.450 |
Why?
|
| Retina | 4 | 2018 | 26 | 0.450 |
Why?
|
| Hand Deformities, Congenital | 3 | 2021 | 25 | 0.440 |
Why?
|
| Hemiplegia | 1 | 2012 | 1 | 0.440 |
Why?
|
| Mice | 16 | 2019 | 737 | 0.440 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 4 | 0.440 |
Why?
|
| Brain | 8 | 2021 | 153 | 0.440 |
Why?
|
| Membrane Proteins | 4 | 2018 | 101 | 0.430 |
Why?
|
| Monomeric GTP-Binding Proteins | 2 | 2014 | 8 | 0.420 |
Why?
|
| Membrane Glycoproteins | 2 | 2019 | 33 | 0.420 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2019 | 31 | 0.420 |
Why?
|
| Dystonia | 3 | 2021 | 8 | 0.410 |
Why?
|
| Trans-Activators | 2 | 2019 | 25 | 0.400 |
Why?
|
| Syndactyly | 3 | 2015 | 13 | 0.400 |
Why?
|
| Fingers | 2 | 2021 | 13 | 0.390 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2010 | 1 | 0.390 |
Why?
|
| Stroke | 1 | 2010 | 17 | 0.380 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 3 | 2021 | 4 | 0.380 |
Why?
|
| Frameshift Mutation | 7 | 2021 | 32 | 0.380 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 83 | 0.380 |
Why?
|
| Centrosome | 5 | 2021 | 9 | 0.370 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2021 | 18 | 0.370 |
Why?
|
| Genes, BRCA1 | 3 | 2020 | 8 | 0.370 |
Why?
|
| Cerebellum | 4 | 2018 | 16 | 0.370 |
Why?
|
| Facies | 7 | 2021 | 40 | 0.360 |
Why?
|
| Muscular Atrophy, Spinal | 2 | 2021 | 12 | 0.360 |
Why?
|
| Kidney Diseases, Cystic | 4 | 2018 | 9 | 0.360 |
Why?
|
| Syndrome | 10 | 2020 | 91 | 0.350 |
Why?
|
| Infant, Newborn | 9 | 2021 | 119 | 0.350 |
Why?
|
| Proteins | 3 | 2016 | 77 | 0.350 |
Why?
|
| Exons | 10 | 2020 | 97 | 0.350 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 148 | 0.350 |
Why?
|
| Ectodermal Dysplasia | 2 | 2021 | 12 | 0.340 |
Why?
|
| Symporters | 2 | 2021 | 3 | 0.340 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2021 | 27 | 0.340 |
Why?
|
| Cataract | 2 | 2020 | 9 | 0.340 |
Why?
|
| Bipolar Disorder | 2 | 2020 | 64 | 0.340 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2016 | 51 | 0.340 |
Why?
|
| Limb Deformities, Congenital | 2 | 2021 | 18 | 0.340 |
Why?
|
| Burkitt Lymphoma | 2 | 2018 | 19 | 0.340 |
Why?
|
| Metabolism, Inborn Errors | 3 | 2013 | 4 | 0.330 |
Why?
|
| Growth Disorders | 4 | 2017 | 25 | 0.330 |
Why?
|
| Hearing Loss | 2 | 2011 | 5 | 0.320 |
Why?
|
| Seizures | 3 | 2017 | 24 | 0.320 |
Why?
|
| GTP-Binding Proteins | 2 | 2021 | 5 | 0.320 |
Why?
|
| Hair Diseases | 3 | 2018 | 14 | 0.320 |
Why?
|
| Genes, BRCA2 | 2 | 2018 | 5 | 0.320 |
Why?
|
| Cleft Lip | 2 | 2021 | 95 | 0.320 |
Why?
|
| Deafness | 2 | 2020 | 8 | 0.320 |
Why?
|
| Software | 2 | 2012 | 133 | 0.320 |
Why?
|
| Muscle Proteins | 3 | 2016 | 11 | 0.310 |
Why?
|
| Genomic Instability | 3 | 2021 | 25 | 0.300 |
Why?
|
| Vesicular Transport Proteins | 2 | 2020 | 17 | 0.300 |
Why?
|
| Protein Conformation | 9 | 2020 | 30 | 0.300 |
Why?
|
| Craniosynostoses | 2 | 2017 | 8 | 0.300 |
Why?
|
| Evolution, Molecular | 3 | 2015 | 114 | 0.300 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2017 | 13 | 0.290 |
Why?
|
| Epilepsy, Benign Neonatal | 2 | 2017 | 3 | 0.290 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2017 | 9 | 0.290 |
Why?
|
| Genotype | 8 | 2020 | 320 | 0.290 |
Why?
|
| Carrier Proteins | 3 | 2018 | 65 | 0.290 |
Why?
|
| Brain Diseases | 3 | 2017 | 15 | 0.280 |
Why?
|
| Pakistan | 7 | 2021 | 12 | 0.280 |
Why?
|
| Dwarfism | 2 | 2015 | 11 | 0.280 |
Why?
|
| Age of Onset | 8 | 2019 | 40 | 0.270 |
Why?
|
| Skin Diseases, Papulosquamous | 2 | 2017 | 9 | 0.270 |
Why?
|
| Hyperpigmentation | 2 | 2017 | 13 | 0.270 |
Why?
|
| Skin Diseases, Genetic | 2 | 2017 | 12 | 0.270 |
Why?
|
| Amino Acid Substitution | 8 | 2016 | 45 | 0.270 |
Why?
|
| Optic Atrophy | 2 | 2017 | 5 | 0.270 |
Why?
|
| Dental Enamel Hypoplasia | 2 | 2015 | 2 | 0.270 |
Why?
|
| Sex Factors | 2 | 2011 | 35 | 0.270 |
Why?
|
| Chorea | 2 | 2016 | 3 | 0.260 |
Why?
|
| Computer Graphics | 1 | 2004 | 10 | 0.250 |
Why?
|
| User-Computer Interface | 1 | 2004 | 19 | 0.250 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 206 | 0.250 |
Why?
|
| Siblings | 6 | 2019 | 28 | 0.250 |
Why?
|
| BRCA2 Protein | 3 | 2020 | 14 | 0.250 |
Why?
|
| BRCA1 Protein | 3 | 2020 | 19 | 0.250 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 2 | 2022 | 2 | 0.240 |
Why?
|
| Risk Factors | 4 | 2018 | 265 | 0.240 |
Why?
|
| Epilepsies, Partial | 2 | 2014 | 11 | 0.240 |
Why?
|
| Founder Effect | 2 | 2021 | 5 | 0.240 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2004 | 13 | 0.240 |
Why?
|
| Channelopathies | 2 | 2021 | 8 | 0.240 |
Why?
|
| Retrospective Studies | 4 | 2020 | 120 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 37 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2018 | 103 | 0.230 |
Why?
|
| Gene Expression | 5 | 2018 | 138 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2018 | 47 | 0.230 |
Why?
|
| Case-Control Studies | 7 | 2018 | 322 | 0.230 |
Why?
|
| Autoimmune Diseases of the Nervous System | 2 | 2014 | 5 | 0.220 |
Why?
|
| Nervous System Malformations | 2 | 2014 | 9 | 0.220 |
Why?
|
| Transcription Factor TFIID | 1 | 2022 | 2 | 0.220 |
Why?
|
| Mutagenesis, Insertional | 1 | 2002 | 11 | 0.220 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 15 | 0.220 |
Why?
|
| Mitochondria | 3 | 2021 | 150 | 0.220 |
Why?
|
| Fetal Diseases | 2 | 2019 | 7 | 0.220 |
Why?
|
| Complement Factor H | 1 | 2022 | 3 | 0.220 |
Why?
|
| Osteochondrodysplasias | 2 | 2017 | 12 | 0.210 |
Why?
|
| Oxidative Stress | 3 | 2017 | 50 | 0.210 |
Why?
|
| Multigene Family | 1 | 2022 | 30 | 0.210 |
Why?
|
| Fibroblasts | 7 | 2017 | 71 | 0.210 |
Why?
|
| Essential Tremor | 1 | 2021 | 5 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 12 | 0.210 |
Why?
|
| Fetal Growth Retardation | 2 | 2018 | 15 | 0.210 |
Why?
|
| Cardiac Conduction System Disease | 1 | 2021 | 1 | 0.210 |
Why?
|
| Troponin I | 1 | 2021 | 2 | 0.210 |
Why?
|
| Endodeoxyribonucleases | 1 | 2021 | 3 | 0.200 |
Why?
|
| Toes | 1 | 2021 | 2 | 0.200 |
Why?
|
| DNA Damage | 3 | 2021 | 77 | 0.200 |
Why?
|
| Hypokinesia | 1 | 2021 | 4 | 0.200 |
Why?
|
| Genes, Modifier | 1 | 2021 | 1 | 0.200 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2021 | 6 | 0.200 |
Why?
|
| Wnt Proteins | 1 | 2021 | 17 | 0.200 |
Why?
|
| Oxidoreductases Acting on Sulfur Group Donors | 1 | 2021 | 1 | 0.200 |
Why?
|
| Muscle Weakness | 1 | 2021 | 5 | 0.200 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2021 | 6 | 0.200 |
Why?
|
| Antigens | 2 | 2021 | 7 | 0.200 |
Why?
|
| DNA Helicases | 2 | 2018 | 17 | 0.200 |
Why?
|
| Cells, Cultured | 6 | 2019 | 261 | 0.200 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2021 | 25 | 0.200 |
Why?
|
| Gene Deletion | 2 | 2018 | 57 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2017 | 11 | 0.190 |
Why?
|
| Hypoglycemia | 1 | 2020 | 4 | 0.190 |
Why?
|
| Receptor, Insulin | 1 | 2020 | 6 | 0.190 |
Why?
|
| DNA Copy Number Variations | 5 | 2019 | 79 | 0.190 |
Why?
|
| Enterocolitis | 1 | 2020 | 2 | 0.190 |
Why?
|
| Ribonucleoproteins, Small Nucleolar | 1 | 2020 | 2 | 0.190 |
Why?
|
| Antigens, CD | 1 | 2020 | 48 | 0.190 |
Why?
|
| Prognosis | 2 | 2018 | 196 | 0.190 |
Why?
|
| Nephrotic Syndrome | 1 | 2020 | 8 | 0.190 |
Why?
|
| Myopia | 1 | 2020 | 3 | 0.190 |
Why?
|
| Lymphokines | 1 | 2020 | 3 | 0.190 |
Why?
|
| Hair | 2 | 2018 | 21 | 0.190 |
Why?
|
| Muscle Hypotonia | 1 | 2020 | 11 | 0.190 |
Why?
|
| Nuclear Envelope | 1 | 2020 | 2 | 0.190 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2020 | 2 | 0.190 |
Why?
|
| RGS Proteins | 1 | 2020 | 5 | 0.190 |
Why?
|
| Mitosis | 3 | 2015 | 8 | 0.180 |
Why?
|
| Hyperekplexia | 1 | 2019 | 2 | 0.180 |
Why?
|
| Glycine Plasma Membrane Transport Proteins | 1 | 2019 | 3 | 0.180 |
Why?
|
| Endoplasmic Reticulum | 3 | 2018 | 22 | 0.180 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2019 | 3 | 0.180 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2019 | 14 | 0.180 |
Why?
|
| Intrinsically Disordered Proteins | 1 | 2019 | 2 | 0.180 |
Why?
|
| Dementia | 1 | 2019 | 3 | 0.180 |
Why?
|
| Receptors, Immunologic | 1 | 2019 | 13 | 0.180 |
Why?
|
| Optic Atrophy, Autosomal Dominant | 1 | 2019 | 2 | 0.180 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2019 | 3 | 0.180 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2017 | 17 | 0.180 |
Why?
|
| Obesity | 1 | 2020 | 86 | 0.180 |
Why?
|
| Cell Line | 5 | 2019 | 137 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 50 | 0.180 |
Why?
|
| Erythromelalgia | 1 | 2019 | 4 | 0.180 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 1 | 2019 | 3 | 0.180 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 27 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 26 | 0.170 |
Why?
|
| Germany | 5 | 2020 | 251 | 0.170 |
Why?
|
| DNA | 2 | 2016 | 102 | 0.170 |
Why?
|
| Polyneuropathies | 1 | 2019 | 16 | 0.170 |
Why?
|
| Protein Isoforms | 4 | 2020 | 37 | 0.170 |
Why?
|
| Signal Transduction | 2 | 2019 | 261 | 0.170 |
Why?
|
| Point Mutation | 2 | 2018 | 36 | 0.170 |
Why?
|
| Pyrroline Carboxylate Reductases | 1 | 2018 | 1 | 0.170 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2018 | 4 | 0.170 |
Why?
|
| Cohort Studies | 5 | 2018 | 191 | 0.170 |
Why?
|
| V(D)J Recombination | 1 | 2018 | 2 | 0.170 |
Why?
|
| Intramolecular Transferases | 1 | 2018 | 3 | 0.170 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2018 | 2 | 0.170 |
Why?
|
| Protein Structure, Tertiary | 5 | 2015 | 40 | 0.170 |
Why?
|
| NAV1.2 Voltage-Gated Sodium Channel | 1 | 2018 | 1 | 0.170 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 44 | 0.170 |
Why?
|
| Speech Disorders | 1 | 2018 | 6 | 0.170 |
Why?
|
| Cerebellar Ataxia | 1 | 2018 | 6 | 0.170 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 6 | 0.170 |
Why?
|
| Neuromuscular Diseases | 1 | 2018 | 5 | 0.170 |
Why?
|
| Bone and Bones | 2 | 2016 | 15 | 0.170 |
Why?
|
| Genome-Wide Association Study | 6 | 2018 | 417 | 0.160 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2018 | 1 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 2 | 2016 | 21 | 0.160 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2018 | 1 | 0.160 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 70 | 0.160 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 60 | 0.160 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2017 | 2 | 0.160 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2017 | 1 | 0.160 |
Why?
|
| Nystagmus, Pathologic | 1 | 2017 | 1 | 0.160 |
Why?
|
| Hypertrichosis | 1 | 2017 | 2 | 0.160 |
Why?
|
| Antiporters | 1 | 2017 | 3 | 0.160 |
Why?
|
| Gain of Function Mutation | 1 | 2017 | 4 | 0.160 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2017 | 2 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 14 | 0.160 |
Why?
|
| DNA, Complementary | 1 | 2017 | 44 | 0.160 |
Why?
|
| Failure to Thrive | 1 | 2017 | 4 | 0.160 |
Why?
|
| Carboplatin | 1 | 2017 | 8 | 0.160 |
Why?
|
| Computational Biology | 2 | 2019 | 164 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 4 | 0.160 |
Why?
|
| Hair Cells, Auditory | 2 | 2015 | 4 | 0.160 |
Why?
|
| Craniofacial Abnormalities | 1 | 2017 | 21 | 0.160 |
Why?
|
| Hypotrichosis | 2 | 2018 | 31 | 0.160 |
Why?
|
| Aging, Premature | 1 | 2017 | 4 | 0.160 |
Why?
|
| Zebrafish Proteins | 1 | 2017 | 11 | 0.160 |
Why?
|
| Muscle Spasticity | 1 | 2017 | 5 | 0.150 |
Why?
|
| Voltage-Gated Sodium Channel beta-1 Subunit | 1 | 2017 | 1 | 0.150 |
Why?
|
| Epileptic Syndromes | 1 | 2017 | 2 | 0.150 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2017 | 6 | 0.150 |
Why?
|
| Movement Disorders | 2 | 2016 | 4 | 0.150 |
Why?
|
| Isoleucine-tRNA Ligase | 1 | 2017 | 2 | 0.150 |
Why?
|
| Growth Hormone | 1 | 2017 | 4 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 32 | 0.150 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2017 | 7 | 0.150 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2017 | 6 | 0.150 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2017 | 2 | 0.150 |
Why?
|
| Hereditary Sensory and Autonomic Neuropathies | 1 | 2017 | 13 | 0.150 |
Why?
|
| Microphthalmos | 1 | 2017 | 5 | 0.150 |
Why?
|
| Nose | 1 | 2017 | 4 | 0.150 |
Why?
|
| Choanal Atresia | 1 | 2017 | 7 | 0.150 |
Why?
|
| Transglutaminases | 1 | 2016 | 3 | 0.150 |
Why?
|
| Hydrolases | 1 | 2016 | 5 | 0.150 |
Why?
|
| Night Blindness | 1 | 2016 | 1 | 0.150 |
Why?
|
| Rhodopsin | 1 | 2016 | 3 | 0.150 |
Why?
|
| Genetic Loci | 5 | 2015 | 120 | 0.150 |
Why?
|
| Intermediate Filament Proteins | 1 | 2016 | 6 | 0.150 |
Why?
|
| Retinitis Pigmentosa | 1 | 2016 | 7 | 0.150 |
Why?
|
| Genes, Dominant | 2 | 2015 | 17 | 0.150 |
Why?
|
| Retinal Dystrophies | 1 | 2016 | 2 | 0.140 |
Why?
|
| Chlorambucil | 1 | 2016 | 1 | 0.140 |
Why?
|
| Abnormal Karyotype | 1 | 2016 | 1 | 0.140 |
Why?
|
| Rituximab | 1 | 2016 | 6 | 0.140 |
Why?
|
| Telomere-Binding Proteins | 1 | 2016 | 4 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 12 | 0.140 |
Why?
|
| Bartter Syndrome | 1 | 2016 | 1 | 0.140 |
Why?
|
| Polyhydramnios | 1 | 2016 | 1 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 14 | 0.140 |
Why?
|
| NAV1.1 Voltage-Gated Sodium Channel | 1 | 2016 | 5 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 38 | 0.140 |
Why?
|
| NAV1.6 Voltage-Gated Sodium Channel | 1 | 2016 | 3 | 0.140 |
Why?
|
| Epilepsy, Frontal Lobe | 1 | 2016 | 1 | 0.140 |
Why?
|
| Myotonia Congenita | 1 | 2016 | 2 | 0.140 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2016 | 2 | 0.140 |
Why?
|
| Selenoproteins | 1 | 2016 | 2 | 0.140 |
Why?
|
| Rickets, Hypophosphatemic | 1 | 2016 | 2 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2016 | 2 | 0.140 |
Why?
|
| Hermanski-Pudlak Syndrome | 1 | 2016 | 1 | 0.140 |
Why?
|
| Adaptor Protein Complex 3 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Adaptor Protein Complex delta Subunits | 1 | 2016 | 1 | 0.140 |
Why?
|
| GTPase-Activating Proteins | 1 | 2016 | 10 | 0.140 |
Why?
|
| Protein Kinases | 1 | 2016 | 11 | 0.140 |
Why?
|
| Diseases in Twins | 1 | 2015 | 2 | 0.140 |
Why?
|
| Deaf-Blind Disorders | 1 | 2015 | 1 | 0.140 |
Why?
|
| Leigh Disease | 1 | 2015 | 4 | 0.140 |
Why?
|
| Lissencephaly | 1 | 2015 | 2 | 0.140 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2015 | 1 | 0.140 |
Why?
|
| Protein Subunits | 1 | 2015 | 15 | 0.140 |
Why?
|
| Adenosine Triphosphatases | 1 | 2015 | 17 | 0.140 |
Why?
|
| Electron Transport Complex IV | 1 | 2015 | 26 | 0.140 |
Why?
|
| Twins, Monozygotic | 1 | 2015 | 10 | 0.140 |
Why?
|
| Citric Acid | 1 | 2015 | 1 | 0.140 |
Why?
|
| Anodontia | 1 | 2015 | 4 | 0.140 |
Why?
|
| Cell Polarity | 1 | 2015 | 5 | 0.140 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2015 | 3 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 4 | 2019 | 32 | 0.140 |
Why?
|
| Eyelid Diseases | 1 | 2015 | 2 | 0.130 |
Why?
|
| Knee | 1 | 2015 | 3 | 0.130 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2015 | 15 | 0.130 |
Why?
|
| Family Health | 4 | 2018 | 24 | 0.130 |
Why?
|
| Epilepsy, Absence | 1 | 2015 | 5 | 0.130 |
Why?
|
| Nails, Malformed | 1 | 2015 | 11 | 0.130 |
Why?
|
| Computing Methodologies | 1 | 2015 | 4 | 0.130 |
Why?
|
| Bone Diseases, Developmental | 1 | 2015 | 5 | 0.130 |
Why?
|
| Whole Genome Sequencing | 3 | 2020 | 27 | 0.130 |
Why?
|
| Lipoylation | 1 | 2015 | 2 | 0.130 |
Why?
|
| Epilepsy, Reflex | 1 | 2015 | 1 | 0.130 |
Why?
|
| Body Height | 1 | 2015 | 11 | 0.130 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2015 | 21 | 0.130 |
Why?
|
| Stereocilia | 1 | 2015 | 1 | 0.130 |
Why?
|
| Receptors, Steroid | 1 | 2015 | 4 | 0.130 |
Why?
|
| Metacarpus | 1 | 2015 | 1 | 0.130 |
Why?
|
| Odontodysplasia | 1 | 2015 | 1 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2015 | 2 | 0.130 |
Why?
|
| DNA Polymerase II | 1 | 2015 | 2 | 0.130 |
Why?
|
| Vascular Calcification | 1 | 2015 | 5 | 0.130 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2015 | 3 | 0.130 |
Why?
|
| Adenoma | 1 | 2015 | 10 | 0.130 |
Why?
|
| Osteoporosis | 1 | 2015 | 6 | 0.130 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 18 | 0.130 |
Why?
|
| SAM Domain and HD Domain-Containing Protein 1 | 2 | 2014 | 6 | 0.130 |
Why?
|
| Pierre Robin Syndrome | 1 | 2014 | 5 | 0.130 |
Why?
|
| Oxidoreductases | 1 | 2014 | 9 | 0.130 |
Why?
|
| Syntaxin 1 | 1 | 2014 | 1 | 0.130 |
Why?
|
| Seizures, Febrile | 1 | 2014 | 2 | 0.130 |
Why?
|
| DNA Primers | 2 | 2014 | 41 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 27 | 0.130 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 143 | 0.130 |
Why?
|
| MERRF Syndrome | 1 | 2014 | 4 | 0.130 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2014 | 4 | 0.130 |
Why?
|
| Prevalence | 3 | 2019 | 46 | 0.130 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2014 | 7 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 14 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 18 | 0.130 |
Why?
|
| Cerebellar Diseases | 1 | 2014 | 4 | 0.130 |
Why?
|
| RecQ Helicases | 1 | 2014 | 2 | 0.130 |
Why?
|
| Exodeoxyribonucleases | 1 | 2014 | 8 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 6 | 0.120 |
Why?
|
| Mice, Knockout | 4 | 2016 | 149 | 0.120 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 133 | 0.120 |
Why?
|
| Glucosyltransferases | 1 | 2014 | 6 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 226 | 0.120 |
Why?
|
| Guanosine Diphosphate Mannose | 1 | 2013 | 2 | 0.120 |
Why?
|
| Antigens, Nuclear | 1 | 2013 | 2 | 0.120 |
Why?
|
| Nucleotidyltransferases | 1 | 2013 | 8 | 0.120 |
Why?
|
| Pain | 1 | 2013 | 9 | 0.120 |
Why?
|
| Pain Perception | 1 | 2013 | 4 | 0.120 |
Why?
|
| Spasms, Infantile | 1 | 2013 | 4 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2013 | 4 | 0.120 |
Why?
|
| Corpus Callosum | 1 | 2013 | 6 | 0.120 |
Why?
|
| Foot Deformities, Congenital | 1 | 2013 | 8 | 0.120 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 20 | 0.120 |
Why?
|
| Neck | 1 | 2013 | 13 | 0.120 |
Why?
|
| Micrognathism | 1 | 2013 | 14 | 0.120 |
Why?
|
| Diacylglycerol Kinase | 1 | 2013 | 1 | 0.120 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2013 | 3 | 0.120 |
Why?
|
| Genes, X-Linked | 1 | 2013 | 6 | 0.120 |
Why?
|
| Ceramides | 1 | 2013 | 6 | 0.120 |
Why?
|
| Ichthyosis, Lamellar | 1 | 2013 | 3 | 0.120 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2013 | 4 | 0.120 |
Why?
|
| Face | 1 | 2013 | 32 | 0.110 |
Why?
|
| Genetic Testing | 3 | 2019 | 66 | 0.110 |
Why?
|
| Striatonigral Degeneration | 1 | 2013 | 2 | 0.110 |
Why?
|
| NADH Dehydrogenase | 1 | 2013 | 5 | 0.110 |
Why?
|
| Axons | 1 | 2013 | 12 | 0.110 |
Why?
|
| Xenopus laevis | 3 | 2017 | 10 | 0.110 |
Why?
|
| Blepharoptosis | 1 | 2012 | 5 | 0.110 |
Why?
|
| Blepharophimosis | 1 | 2012 | 4 | 0.110 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2012 | 5 | 0.110 |
Why?
|
| Vitamin B 12 | 1 | 2012 | 1 | 0.110 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2012 | 21 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 16 | 0.110 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 43 | 0.110 |
Why?
|
| Bone Morphogenetic Protein 1 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Sensory Gating | 1 | 2012 | 3 | 0.110 |
Why?
|
| Osteogenesis | 1 | 2012 | 4 | 0.110 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2012 | 5 | 0.110 |
Why?
|
| Smoking | 1 | 2012 | 14 | 0.110 |
Why?
|
| Alternative Splicing | 2 | 2018 | 28 | 0.110 |
Why?
|
| Prune Belly Syndrome | 1 | 2011 | 1 | 0.100 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Urinary Bladder | 1 | 2011 | 6 | 0.100 |
Why?
|
| HEK293 Cells | 3 | 2016 | 64 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2012 | 74 | 0.100 |
Why?
|
| Keratinocytes | 3 | 2018 | 20 | 0.100 |
Why?
|
| Protein Transport | 3 | 2019 | 31 | 0.100 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 15 | 0.100 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 2 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2015 | 15 | 0.100 |
Why?
|
| Cytokines | 1 | 2010 | 75 | 0.090 |
Why?
|
| HeLa Cells | 3 | 2016 | 62 | 0.090 |
Why?
|
| Microsatellite Repeats | 2 | 2014 | 34 | 0.090 |
Why?
|
| Sequence Alignment | 3 | 2014 | 83 | 0.090 |
Why?
|
| Family | 2 | 2020 | 36 | 0.090 |
Why?
|
| Central Nervous System Cysts | 1 | 2009 | 1 | 0.090 |
Why?
|
| Ribonucleases | 1 | 2009 | 2 | 0.090 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2009 | 5 | 0.090 |
Why?
|
| Introns | 2 | 2021 | 60 | 0.090 |
Why?
|
| Genome, Human | 2 | 2021 | 104 | 0.090 |
Why?
|
| Genomics | 2 | 2021 | 143 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2019 | 40 | 0.080 |
Why?
|
| Migraine with Aura | 1 | 2008 | 1 | 0.080 |
Why?
|
| RNA Splice Sites | 2 | 2021 | 13 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2008 | 13 | 0.080 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 2 | 2018 | 6 | 0.080 |
Why?
|
| Disease Progression | 2 | 2019 | 72 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2019 | 186 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2018 | 16 | 0.080 |
Why?
|
| Oocytes | 2 | 2017 | 14 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2017 | 16 | 0.070 |
Why?
|
| Workflow | 2 | 2018 | 21 | 0.070 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2018 | 24 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2017 | 174 | 0.070 |
Why?
|
| DNA, Mitochondrial | 2 | 2017 | 65 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2019 | 263 | 0.070 |
Why?
|
| Gene Order | 2 | 2015 | 4 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2016 | 15 | 0.070 |
Why?
|
| Cilia | 2 | 2015 | 5 | 0.070 |
Why?
|
| Kidney | 2 | 2016 | 38 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2019 | 199 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 210 | 0.070 |
Why?
|
| Calpain | 1 | 2005 | 9 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2015 | 129 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2014 | 42 | 0.060 |
Why?
|
| Spinal Diseases | 1 | 2004 | 1 | 0.060 |
Why?
|
| Sulfotransferases | 1 | 2004 | 2 | 0.060 |
Why?
|
| Pelizaeus-Merzbacher Disease | 1 | 2004 | 4 | 0.060 |
Why?
|
| Connexins | 1 | 2004 | 6 | 0.060 |
Why?
|
| Cysteine | 1 | 2004 | 5 | 0.060 |
Why?
|
| GPI-Linked Proteins | 1 | 2004 | 15 | 0.060 |
Why?
|
| Electroencephalography | 2 | 2015 | 13 | 0.060 |
Why?
|
| Age Factors | 1 | 2004 | 56 | 0.060 |
Why?
|
| Nervous System Diseases | 2 | 2013 | 13 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 78 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2015 | 120 | 0.060 |
Why?
|
| Microtubules | 2 | 2013 | 16 | 0.060 |
Why?
|
| Lysosome-Associated Membrane Glycoproteins | 2 | 2013 | 4 | 0.060 |
Why?
|
| Hungary | 1 | 2002 | 2 | 0.060 |
Why?
|
| Sequence Homology | 1 | 2002 | 2 | 0.060 |
Why?
|
| TATA-Box Binding Protein | 1 | 2022 | 1 | 0.060 |
Why?
|
| Atrophy | 1 | 2022 | 7 | 0.060 |
Why?
|
| RNA Polymerase II | 1 | 2022 | 12 | 0.060 |
Why?
|
| Binding Sites | 2 | 2017 | 73 | 0.050 |
Why?
|
| Complement C3b Inactivator Proteins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 16 | 0.050 |
Why?
|
| NAV1.4 Voltage-Gated Sodium Channel | 1 | 2021 | 1 | 0.050 |
Why?
|
| Codon, Initiator | 1 | 2021 | 2 | 0.050 |
Why?
|
| Tongue | 1 | 2021 | 2 | 0.050 |
Why?
|
| Models, Biological | 2 | 2017 | 115 | 0.050 |
Why?
|
| RNA, Transfer | 1 | 2021 | 8 | 0.050 |
Why?
|
| Telomere Shortening | 1 | 2021 | 7 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2021 | 19 | 0.050 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 11 | 0.050 |
Why?
|
| Sudan | 1 | 2021 | 1 | 0.050 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2021 | 2 | 0.050 |
Why?
|
| Morocco | 1 | 2021 | 2 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 90 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2020 | 12 | 0.050 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 2 | 0.050 |
Why?
|
| Infant Mortality | 1 | 2020 | 3 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2020 | 9 | 0.050 |
Why?
|
| Dehydration | 1 | 2020 | 4 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 21 | 0.050 |
Why?
|
| Amino Acid Motifs | 2 | 2014 | 14 | 0.050 |
Why?
|
| Germ Cells | 1 | 2020 | 30 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2020 | 4 | 0.050 |
Why?
|
| RNA, Ribosomal | 1 | 2020 | 7 | 0.050 |
Why?
|
| Saudi Arabia | 1 | 2020 | 4 | 0.050 |
Why?
|
| Egypt | 1 | 2020 | 2 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2020 | 4 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 66 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2020 | 7 | 0.050 |
Why?
|
| Apnea | 1 | 2019 | 2 | 0.050 |
Why?
|
| Longevity | 1 | 2020 | 40 | 0.050 |
Why?
|
| Arthrogryposis | 1 | 2019 | 9 | 0.050 |
Why?
|
| Malformations of Cortical Development, Group I | 1 | 2019 | 1 | 0.040 |
Why?
|
| Ganglioglioma | 1 | 2019 | 2 | 0.040 |
Why?
|
| Sclerosis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2019 | 33 | 0.040 |
Why?
|
| Glioma | 1 | 2019 | 12 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 1 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 8 | 0.040 |
Why?
|
| Wallerian Degeneration | 1 | 2019 | 2 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2019 | 11 | 0.040 |
Why?
|
| Lamin Type A | 1 | 2018 | 1 | 0.040 |
Why?
|
| Cuba | 1 | 2018 | 4 | 0.040 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2018 | 1 | 0.040 |
Why?
|
| Penetrance | 1 | 2018 | 15 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 35 | 0.040 |
Why?
|
| Cholesterol | 1 | 2018 | 22 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 99 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 99 | 0.040 |
Why?
|
| Molar | 1 | 2018 | 1 | 0.040 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2018 | 4 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 7 | 0.040 |
Why?
|
| Autistic Disorder | 1 | 2018 | 12 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2018 | 19 | 0.040 |
Why?
|
| Alopecia | 1 | 2018 | 35 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 41 | 0.040 |
Why?
|
| Protein Interaction Mapping | 1 | 2018 | 24 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 60 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2018 | 45 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 92 | 0.040 |
Why?
|
| Electrophysiology | 1 | 2017 | 3 | 0.040 |
Why?
|
| Cutis Laxa | 1 | 2017 | 1 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 2017 | 5 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2017 | 8 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2017 | 9 | 0.040 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Pharmacogenomic Variants | 1 | 2017 | 3 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 27 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2017 | 22 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 54 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2017 | 16 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 56 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2017 | 115 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2017 | 15 | 0.040 |
Why?
|
| Radiography | 1 | 2017 | 11 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 68 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 161 | 0.040 |
Why?
|
| Glutathione | 1 | 2017 | 8 | 0.040 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2017 | 1 | 0.040 |
Why?
|
| Apoptosis | 1 | 2017 | 94 | 0.040 |
Why?
|
| Cell Size | 1 | 2016 | 3 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2016 | 3 | 0.040 |
Why?
|
| Organ Size | 1 | 2016 | 9 | 0.040 |
Why?
|
| Acyltransferases | 1 | 2016 | 11 | 0.040 |
Why?
|
| Vibrissae | 1 | 2016 | 3 | 0.040 |
Why?
|
| Schiff Bases | 1 | 2016 | 1 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2017 | 43 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 40 | 0.040 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2016 | 5 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2016 | 26 | 0.040 |
Why?
|
| Cell Movement | 1 | 2016 | 45 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 73 | 0.040 |
Why?
|
| Hernia | 1 | 2016 | 1 | 0.040 |
Why?
|
| Joint Instability | 1 | 2016 | 2 | 0.040 |
Why?
|
| Psychomotor Disorders | 1 | 2016 | 3 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2016 | 39 | 0.040 |
Why?
|
| Solute Carrier Family 12, Member 1 | 1 | 2016 | 1 | 0.040 |
Why?
|
| Sodium Chloride Symporters | 1 | 2016 | 2 | 0.040 |
Why?
|
| Fetal Death | 1 | 2016 | 3 | 0.040 |
Why?
|
| Fetus | 1 | 2016 | 9 | 0.040 |
Why?
|
| Premature Birth | 1 | 2016 | 8 | 0.040 |
Why?
|
| Argentina | 1 | 2016 | 2 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 102 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2016 | 4 | 0.040 |
Why?
|
| Lod Score | 1 | 2016 | 7 | 0.030 |
Why?
|
| Endonucleases | 1 | 2016 | 6 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2016 | 11 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 15 | 0.030 |
Why?
|
| Hernia, Umbilical | 1 | 2015 | 1 | 0.030 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2015 | 2 | 0.030 |
Why?
|
| Ameloblasts | 1 | 2015 | 1 | 0.030 |
Why?
|
| Odontoblasts | 1 | 2015 | 1 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 2015 | 2 | 0.030 |
Why?
|
| Pregnancy | 1 | 2016 | 113 | 0.030 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2015 | 3 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2016 | 9 | 0.030 |
Why?
|
| Chromosome Segregation | 1 | 2015 | 3 | 0.030 |
Why?
|
| White Matter | 1 | 2015 | 6 | 0.030 |
Why?
|
| Kinetochores | 1 | 2015 | 2 | 0.030 |
Why?
|
| S Phase | 1 | 2015 | 2 | 0.030 |
Why?
|
| Replication Protein A | 1 | 2015 | 3 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 51 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2016 | 7 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 21 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2015 | 14 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 51 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2015 | 55 | 0.030 |
Why?
|
| Structural Homology, Protein | 1 | 2015 | 5 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 36 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 48 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2015 | 31 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 4 | 0.030 |
Why?
|
| Landau-Kleffner Syndrome | 1 | 2015 | 2 | 0.030 |
Why?
|
| Turkey | 1 | 2015 | 13 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2015 | 2 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 28 | 0.030 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Arteries | 1 | 2015 | 2 | 0.030 |
Why?
|
| Tooth Abnormalities | 1 | 2015 | 2 | 0.030 |
Why?
|
| Interferon-beta | 1 | 2015 | 4 | 0.030 |
Why?
|
| Phospholipase D | 1 | 2015 | 4 | 0.030 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2015 | 4 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2015 | 9 | 0.030 |
Why?
|
| Calcinosis | 1 | 2015 | 6 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2015 | 13 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 62 | 0.030 |
Why?
|
| Gene Components | 1 | 2014 | 4 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 8 | 0.030 |
Why?
|
| Centrioles | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2014 | 13 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 32 | 0.030 |
Why?
|
| Genes, cdc | 1 | 2014 | 3 | 0.030 |
Why?
|
| Temperature | 1 | 2014 | 29 | 0.030 |
Why?
|
| DNA Replication | 1 | 2014 | 11 | 0.030 |
Why?
|
| Iraq | 1 | 2014 | 1 | 0.030 |
Why?
|
| Leber Congenital Amaurosis | 1 | 2014 | 1 | 0.030 |
Why?
|
| Werner Syndrome Helicase | 1 | 2014 | 2 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 3 | 0.030 |
Why?
|
| Austria | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2014 | 64 | 0.030 |
Why?
|
| Werner Syndrome | 1 | 2014 | 2 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 93 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 71 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2015 | 82 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 58 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2013 | 4 | 0.030 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2013 | 2 | 0.030 |
Why?
|
| Adrenal Insufficiency | 1 | 2013 | 3 | 0.030 |
Why?
|
| Glycosylation | 1 | 2013 | 4 | 0.030 |
Why?
|
| Action Potentials | 1 | 2013 | 9 | 0.030 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2013 | 4 | 0.030 |
Why?
|
| Nociceptors | 1 | 2013 | 6 | 0.030 |
Why?
|
| Esophageal Achalasia | 1 | 2013 | 5 | 0.030 |
Why?
|
| RNA Splicing Factors | 1 | 2013 | 8 | 0.030 |
Why?
|
| NAV1.9 Voltage-Gated Sodium Channel | 1 | 2013 | 6 | 0.030 |
Why?
|
| Skin | 1 | 2014 | 42 | 0.030 |
Why?
|
| SMARCB1 Protein | 1 | 2013 | 4 | 0.030 |
Why?
|
| Karyotyping | 1 | 2013 | 28 | 0.030 |
Why?
|
| Syria | 1 | 2013 | 1 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2013 | 7 | 0.030 |
Why?
|
| Ataxia | 1 | 2013 | 7 | 0.030 |
Why?
|
| Lysosomes | 1 | 2013 | 7 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2013 | 6 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2013 | 20 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2013 | 6 | 0.030 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2013 | 1 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2013 | 7 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 8 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 3 | 0.030 |
Why?
|
| Epidermis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2013 | 48 | 0.030 |
Why?
|
| Xenopus | 1 | 2013 | 5 | 0.030 |
Why?
|
| Protein Binding | 1 | 2013 | 97 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 5 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 9 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2013 | 18 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2012 | 8 | 0.030 |
Why?
|
| Rats | 1 | 2013 | 164 | 0.030 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2012 | 1 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2012 | 2 | 0.030 |
Why?
|
| Collagen | 1 | 2012 | 5 | 0.030 |
Why?
|
| Cotinine | 1 | 2012 | 2 | 0.030 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 2 | 0.030 |
Why?
|
| Transcription Factor 4 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2012 | 5 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2012 | 3 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 12 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2012 | 13 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2012 | 20 | 0.030 |
Why?
|
| Geography | 1 | 2012 | 14 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 9 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2012 | 11 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2012 | 26 | 0.030 |
Why?
|
| RNA Interference | 1 | 2012 | 48 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2012 | 46 | 0.030 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2011 | 3 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2011 | 12 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 92 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2011 | 26 | 0.030 |
Why?
|
| Cochlea | 1 | 2011 | 4 | 0.030 |
Why?
|
| Ear, Inner | 1 | 2011 | 6 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 4 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2004 | 7 | 0.020 |
Why?
|
| Nervous System | 1 | 2004 | 5 | 0.020 |
Why?
|
